Nanoform nominated for CPhI Award!
We are delighted to have been shortlisted as a finalist for the CPhI Award in the Excellence in Pharma: Formulation category.
Nanoform and AstraZeneca Initiate Technology Evaluation
Nanoform is delighted to announce the initiation of a technology evaluation of Nanoform’s Proprietary CESS Technology across a range of AstraZeneca’s proprietary pharmaceutical products.
Nanoform strengthens board with appointment of Mads Laustsen
Nanoform has appointed Mads Laustsen as a non-executive board member. This appointment will further strengthen the experienced Nanoform board and support the company as it increases its ability to deliver nanonized APIs for global partners across the pipeline from late stage drug discovery to commercial.
Nanoform appoints Mike Rea as Strategic Innovation Advisor
Nanoform has appointed Mike Rea as its Strategic Innovation Advisor. The role will involve working closely with Nanoform to maximise the value its proprietary nanonization technology can deliver to pharmaceutical partners and patients globally.
Chemistry World
Our scientists discuss the advantages of applying a multidisciplinary approach…
Cleanroom Technology
Our CTO, Niklas Sandler, discusses the growing demand for nanoformed…
Nanoform appoints Director of Investor Relations following international growth
Nanoform has appointed Henri von Haartman as Director of Investor Relations. The newly created role will enrich investor relations as Nanoform seeks to further its shareholder base and continue its international growth, including expansion into the US market.
Nanoform continues strategic growth with €10 million private placement
Nanoform announced the completion of a private placement totaling €10 million, with Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acting as anchor investors.